|
1
|
Swetter SM, Boldrick JC, Jung SY, Egbert BM and Harvell JD: Increasing incidence of lentigo maligna melanoma subtypes: Northern California and national trends 1990-2000. J Invest Dermatol. 125:685–691. 2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Greveling K, Wakkee M, Nijsten T, van den Bos RR and Hollestein LM: Epidemiology of lentigo maligna and lentigo maligna melanoma in the Netherlands, 1989-2013. J Invest Dermatol. 136:1955–1960. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Matas-Nadal C, Sòria X, García-de-la-Fuente MR, Huerva V, Ortega E, Vilardell F, Gatius S, Casanova JM and Martí RM: Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma. J Dermatol. 45:564–570. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Guitera P, Collgros H, Madronio C, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, et al: The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management. Australas J Dermatol. 60:118–125. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Higgins H II, Cho E, Weinstock MA, Li TY, Qureshi A and Li WQ: Gender differences, UV exposure and risk of lentigo maligna in a nationwide healthcare population cohort study. J Eur Acad Dermatol Venereol. 33:1268–1271. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Duarte AF, Sousa-Pinto B, Barros AM, Haneke E and Correia O: Lentigo maligna-not always a face and neck disease of the elderly. Dermatology. 234:37–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Menzies SW, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S, Armstrong B, Scolyer RA and Guitera P: Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Res. 30:193–197. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cinotti E, Labeille B, Debarbieux S, Carrera C, Lacarrubba F, Witkowski AM, Moscarella E, Arzberger E, Kittler H, Bahadoran P, et al: Dermoscopy vs reflectance confocal microscopy for the diagnosis of lentigo maligna. J Eur Acad Dermatol Venereol. 32:1284–1291. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pralong P, Bathelier E, Dalle S, Poulalhon N, Debarbieux S and Thomas L: Dermoscopy of lentigo maligna melanoma: Report of 125 cases. Br J Dermatol. 167:280–287. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Agozzino M, Vitiello P and Nuzzo T: Lentigo maligna. In: Argenziano G, Moscarella E, Piccolo V, Agozzino M, Longo C, Pellacani G (eds). Color Atlas of Dermoscopy PICCIN press, Padova, pp127-129, 2020.
|
|
11
|
Tiodorovic-Zivkovic D, Argenziano G, Lallas A, Thomas L, Ignjatovic A, Rabinovitz H, Moscarella E, Longo C, Hofmann-Wellenhof R and Zalaudek I: Age, gender, and topography influence the clinical and dermoscopic appearance of lentigo maligna. J Am Acad Dermatol. 72:801–808. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Winkler JK, Sies K, Fink C, Toberer F, Enk A, Deinlein T, Hofmann-Wellenhof R, Thomas L, Lallas A, Blum A, et al: Melanoma recognition by a deep learning convolutional neural network-performance in different melanoma subtypes and localisations. Eur J Cancer. 127:21–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Guitera P, Moloney FJ, Menzies SW, Stretch JR, Quinn MJ, Hong A, Fogarty G and Scolyer RA: Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. JAMA Dermatol. 149:692–698. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lallas A, Argenziano G, Moscarella E, Longo C, Simonetti V and Zalaudek I: Diagnosis and management of facial pigmented macules. Clin Dermatol. 32:94–100. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Star P and Guitera P: Lentigo maligna, macules of the face, and lesions on sun-damaged skin: Confocal makes the difference. Dermatol Clin. 34:421–429. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P and Kelly JW: The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: Experience of an Australian tertiary referral service. Arch Dermatol. 146:234–239. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Champin J, Perrot JL, Cinotti E, Labeille B, Douchet C, Parrau G, Cambazard F, Seguin P and Alix T: In vivo reflectance confocal microscopy to optimize the spaghetti technique for defining surgical margins of lentigo maligna. Dermatol Surg. 40:247–256. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yelamos O, Cordova M, Blank N, Kose K, Dusza SW, Lee E, Rajadhyaksha M, Nehal KS and Rossi AM: Correlation of handheld reflectance confocal microscopy with radial video mosaicing for margin mapping of lentigo maligna and lentigo maligna melanoma. JAMA Dermatol. 153:1278–1284. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Agarwal-Antal N, Bowen GM and Gerwels JW: Histologic evaluation of lentigo maligna with permanent sections: Implications regarding current guidelines. J Am Acad Dermatol. 47:743–748. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Möller M, Pappas-Politis E, Zager JS, Santiago LA, Yu D, Prakash A, Kinal A, Clark GS, Zhu W, Puleo CA, et al: Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 16:1526–1536. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zoutendijk J, Tio D, Koljenovic S and van den Bos RR: Nine per cent of biopsy-proven lentigo maligna lesions are reclassified as lentigo maligna melanoma after surgery. Br J Dermatol. 181:383–384. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Connolly KL, Giordano C, Dusza S, Busam KJ and Nehal K: Follicular involvement is frequent in lentigo maligna: Implications for treatment. J Am Acad Dermatol. 80:532–537. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Elder DE, Bastian BC, Kim J, Massi D, Mihm M, Scolyer R and Wood B: Lentigo maligna melanoma. In: WHO Classification of Skin Tumours. 4th edition. Elder DE, Massi D, Scolyer RA and Willemze R (eds). International Agency for Research on Cancer, Lyon, pp102-104, 2018.
|
|
24
|
Tio D, Willemsen M, Krebbers G, Kasiem FR, Hoekzema R, van Doorn R, Bekkenk MW and Luiten RM: Differential expression of cancer testis antigens on lentigo maligna and lentigo maligna melanoma. Am J Dermatopathol. 42:625–627. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Elder DE, Bastian BC, Cree IA, Massi D and Scolyer RA: The 2018 world health organization classification of cutaneous, mucosal and uveal melanoma. Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 144:500–522. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P and Apalla Z: Interventions for melanoma in situ, including lentigo maligna. Cochrane Database Syst Rev: Dec 19, 2014. doi: 10.1002/14651858.CD010308.pub2.
|
|
27
|
McLeod M, Choudhary S, Giannakakis G and Nouri K: Surgical treatments for lentigo maligna: A review. Dermatol Surg. 37:1210–1228. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
de Vries K, Greveling K, Prens LM, Munte K, Koljenović S, van Doorn MB and Prens EP: Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. Br J Dermatol. 174:588–593. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Demer AM, Hanson JL, Maher IA and Liszewski W: Association of Mohs micrographic surgery vs wide local excision with overall survival outcomes for patients with melanoma of the trunk and extremities. JAMA Dermatol. 157:84–89. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
McGuire LK, Disa JJ, Lee EH, Busam KJ and Nehal KS: Melanoma of the lentigo maligna subtype: Diagnostic challenges and current treatment paradigms. Plast Reconstr Surg. 129:288e–299e. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC and Nehal KS: Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol. 58:142–148. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ellison PM, Zitelli JA and Brodland DG: Mohs micrographic surgery for melanoma: A prospective multicenter study. J Am Acad Dermatol. 81:767–774. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kunishige JH, Brodland DG and Zitelli JA: Surgical margins for melanoma in situ. J Am Acad Dermatol. 66:438–444. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, et al: French updated recommendations in stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol. 31:594–602. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, et al: European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-update 2019. Eur J Cancer. 126:159–177. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed December 19, 2020.
|
|
37
|
Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, et al: Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 80:208–250. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gradecki SE, Valdes-Rodriguez R, Wick MR and Gru AA: PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology: Dec 6, 2020 (Epub ahead of print).
|
|
39
|
Gaudy-Marqueste C, Perchenet AS, Taséi AM, Madjlessi N, Magalon G, Richard MA and Grob JJ: The ‘spaghetti technique’: An alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol. 64:113–118. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Connolly KL, Hibler BP, Lee EH, Rossi AM, Busam KJ and Nehal KS: Locally recurrent lentigo maligna and lentigo maligna melanoma: Characteristics and time to recurrence after surgery. Dermatol Surg. 43:792–797. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Johnson TM, Headington JT, Baker SR and Lowe L: Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: The ‘square’ procedure. J Am Acad Dermatol. 37:758–764. 1997.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Smith H, Olabi B, Lam M, Patel A and Varma S: Ten years' experience using the Johnson square procedure for lentigo maligna. Br J Dermatol. 181:602–604. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hilari H, Llorca D, Traves V, Villanueva A, Serra-Guillén C, Requena C, Llombart B, Sanmartín O, Guillén C and Nagore E: Conventional surgery compared with slow Mohs micrographic surgery in the treatment of lentigo maligna: A retrospective study of 62 cases. Actas Dermosifiliogr. 103:614–623. 2012.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).
|
|
44
|
Bene NI, Healy C and Coldiron BM: Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: A prospective study of 167 cases. Dermatol Surg. 34:660–664. 2008.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Erickson C and Miller SJ: Treatment options in melanoma in situ: Topical and radiation therapy, excision and Mohs surgery. Int J Dermatol. 49:482–491. 2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sharma AN, Foulad DP, Doan L, Lee PK and Atanaskova Mesinkovska N: Mohs surgery for the treatment of lentigo maligna and lentigo maligna melanoma-a systematic review. J Dermatolog Treat. 32:157–163. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Walling HW, Scupham RK, Bean AK and Ceilley RI: Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 57:659–664. 2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zitelli JA, Brown C and Hanusa BH: Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 37:236–245. 1997.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Stigall LE, Brodland DG and Zitelli JA: The use of Mohs micrographic surgery (MMS) for melanoma in situ (MIS) of the trunk and proximal extremities. J Am Acad Dermatol. 75:1015–1021. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R and Keilholz U: ESMO Guidelines Committee. Electronic address: simpleclinicalguidelines@esmo.org: Cutaneous melanoma. ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 30:1884–1901. 2019.
|
|
51
|
Hendrickx A, Cozzio A, Plasswilm L and Panje CM: Radiotherapy for lentigo maligna and lentigo maligna melanoma-a systematic review. Radiat Oncol. 15(174)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Fogarty GB, Hong A, Economides A and Guitera P: Experience with treating radiotherapy for lentigo maligna with definitive radiotherapy. Dermatol Res Pract. 2018(7439807)2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, Plewig G and Volkenandt M: Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 43:477–482. 2000.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lazarevic D, Ramelyte E, Dummer R and Imhof L: Radiotherapy in periocular cutaneous malignancies: A retrospective study. Dermatology. 235:234–239. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hedblad MA and Mallbris L: Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol. 67:60–68. 2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kopf AW, Bart RS and Gladstein AH: Treatment of melanotic freckle with x-rays. Arch Dermatol. 112:801–807. 1976.PubMed/NCBI
|
|
57
|
Lamoureux A, Ouhabrache N, Coulibaly S, Dousset L, Gerard E, Dutriaux C, Pham-Ledard A, Cogrel O, Trouette R, Beylot-Barry M and Vendrely V: Contact radiotherapy for lentigo maligna and lentigo maligna melanoma: A cohort of 61 cases. Radiother Oncol. 127(S436)2018.
|
|
58
|
Zalaudek I, Horn M, Richtig E, Hödl S, Kerl H and Smolle J: Local recurrence in melanoma in situ: Influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol. 148:703–708. 2003.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Farshad A, Burg G, Panizzon R and Dummer R: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 146:1042–1046. 2002.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Christie DR and Tiver KW: Radiotherapy for melanotic freckles. Australas Radiol. 40:331–333. 1996.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Tsang RW, Liu FF, Wells W and Payne DG: Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol. 130:1008–1012. 1994.PubMed/NCBI
|
|
62
|
Harwood AR: Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys. 9:1019–1021. 1983.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Robinson M, Primiero C, Guitera P, Hong A, Scolyer RA, Stretch JR, Strutton G, Thompson JF and Soyer HP: Evidence-based clinical practice guidelines for the management of patients with lentigo maligna. Dermatology. 236:111–116. 2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Papanikolaou M and Lawrence CM: Long-term outcomes of imiquimod-treated lentigo maligna. Clin Exp Dermatol. 44:631–636. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Sampson BP and Bowen GM: Strategies for reducing final surgical defect sizes in the treatment of lentigo maligna. Dermatol Surg. 46:537–545. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Kai AC, Richards T, Coleman A, Mallipeddi R, Barlow R and Craythorne EE: Five-year recurrence rate of lentigo maligna after treatment with imiquimod. Br J Dermatol. 174:165–168. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Astorino S, Astorre P, Pasquini P, Di Nunno D, Pellegrini F and Paolino G: Imiquimod 5% cream in occlusion, for the treatment of lentigo maligna: A new scheme of short cycles and the need for clinical trials. Dermatol Ther. 32(e12757)2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Buettiker UV, Yawalkar NY, Braathen LR and Hunger RE: Imiquimod treatment of lentigo maligna: An open-label study of 34 primary lesions in 32 patients. Arch Dermatol. 144:943–945. 2008.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Chapman MS, Spencer SK and Brennick JB: Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 139:943–944. 2003.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Cotter MA, McKenna JK and Bowen GM: Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 34:147–151. 2008.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Wong JG, Toole JW, Demers AA, Musto G and Wiseman MC: Topical 5% imiquimod in the treatment of lentigo maligna. J Cutan Med Surg. 16:245–249. 2012.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Kirtschig G, Van Meurs T and Van Doorn R: Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate. Acta Derm Venereol. 95:83–85. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Gautschi M, Oberholzer PA, Baumgartner M, Gadaldi K, Yawalkar N and Hunger RE: Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study. J Am Acad Dermatol. 74:81–87.e1. 2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Read T, Noonan C, David M, Wagels M, Foote M, Schaider H, Soyer HP and Smithers BM: A systematic review of non-surgical treatments for lentigo maligna. J Eur Acad Dermatol Venereol. 30:748–753. 2016.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Greveling K, van der Klok T, van Doorn MB, Noordhoek Hegt V and Prens EP: Lentigo maligna-anatomic location as a potential risk factor for recurrences after non-surgical treatment. J Eur Acad Dermatol Venereol. 31:450–454. 2017.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Craythorne EE and Lawrence CM: Observational study of topical imiquimod immunotherapy in the treatment of difficult lentigo maligna. Clin Med Oncol. 2:551–554. 2008.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Powell AM, Robson AM, Russell-Jones R and Barlow RJ: Imiquimod and lentigo maligna: A search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 160:994–998. 2009.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Ly L, Kelly JW, O'Keefe R, Sutton T, Dowling JP, Swain S, Byrne M, Curr N, Wolfe R, Chamberlain A and Haskett M: Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: A study of 43 patients. Arch Dermatol. 147:1191–1195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Halse H, Caramia F, McLean CA, Wang M, Aw Yeang HX, Keam SP, Behren A, Ly L, Haskett M, Cebon J, et al: Distinct pretreatment immune gene signature in lentigo maligna is associated with imiquimod response. J Invest Dermatol. 140:869–877.e16. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D and Bowen GM: A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 148:592–596. 2012.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Donigan JM, Hyde MA, Goldgar DE, Hadley ML, Bowling M and Bowen GM: Rate of recurrence of lentigo maligna with off-label neoadjuvant topical imiquimod, 5%, cream prior to conservatively staged excision. JAMA Dermatol. 154:885–988. 2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Mora AN, Karia PS and Nguyen BM: A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 73:205–212. 2015.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Marsden JR, Fox R, Boota NM, Cook M, Wheatley K, Billingham LJ and Steven NM: NCRI Skin Cancer Clinical Studies Group, the U.K. Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group. Effect of topical imiquimod as primary treatment for lentigo maligna: The LIMIT-1 study. Br J Dermatol. 176:1148–1154. 2017.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Rajpar SF and Marsden JR: Imiquimod in the treatment of lentigo maligna. Br J Dermatol. 155:653–656. 2006.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Tio D, van der Woude J, Prinsen CAC, Jansma EP, Hoekzema R and van Montfrans C: A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: Need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 31:616–624. 2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Woodmansee CS and McCall MW: Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatol Surg. 35:1286–1289. 2009.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Ellis LZ, Cohen JL, High W and Stewart L: Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: Review of the literature. Dermatol Surg. 38:937–946. 2012.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Brand FL, Seyed Jafari SM and Hunger RE: Confocal microscopy and lentigo maligna: An in vivo pilot study for the assessment of response to imiquimod therapy. Dermatology. 235:150–155. 2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
De Moraes AM, Pavarin LB, Herreros F, de Aguiar Michelman F, Velho PE and de Souza EM: Cryosurgical treatment of lentigo maligna. J Dtsch Dermatol Ges. 5:477–480. 2007.PubMed/NCBI View Article : Google Scholar : (In English, German).
|
|
90
|
Collins P, Rogers S, Goggin M and Manning W: Cryotherapy for lentigo maligna. Clin Exp Dermatol. 16:433–435. 1991.PubMed/NCBI View Article : Google Scholar
|
|
91
|
McKenna JK, Florell SR, Goldman GD and Bowen GM: Lentigo maligna/lentigo maligna melanoma: Current state of diagnosis and treatment. Dermatol Surg. 32:493–504. 2006.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Karam A, Simon M, Lemasson G and Misery L: The use of photodynamic therapy in the treatment of lentigo maligna. Pigment Cell Melanoma Res. 26:275–277. 2013.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Räsänen JE, Neittaanmäki N, Jeskanen L, Pölönen I, Snellman E and Grönroos M: Ablative fractional laser-assisted photodynamic therapy for lentigo maligna: A prospective pilot study. J Eur Acad Dermatol Venereol. 34:510–517. 2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Lee H, Sowerby LJ, Temple CL, Yu E and Moore CC: Carbon dioxide laser treatment for lentigo maligna: A retrospective review comparing 3 different treatment modalities. Arch Facial Plast Surg. 13:398–403. 2011.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Madal V and August PJ: Lentigo maligna-outcomes of treatment with Q-switched Nd:YAG and alexandrite lasers. Dermatol Surg. 35:607–612. 2009.PubMed/NCBI View Article : Google Scholar
|
|
96
|
de Vries K, Rellum R, Habets JM and Prens EP: A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod. Br J Dermatol. 168:1362–1364. 2013.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Fikrle T, Divišová B, Šuchmannová J and Pizinger K: The use of 2940-nm ER:YAG laser for the treatment of lentigo maligna. J Dtsch Dermatol Ges. 17:425–431. 2019.PubMed/NCBI View Article : Google Scholar
|
|
98
|
McKenna DB, Cooper EJ, Kavanagh GM, Davie RM, McLaren KM and Tidman MJ: Amelanotic malignant melanoma following cryosurgery for atypical lentigo maligna. Clin Exp Dermatol. 25:600–604. 2000.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Nazzaro-Porro M, Passi S, Zina G and Breathnach AS: Ten year's experience of treating lentigo maligna with topical azelaic acid. Acta Derm Venereol Suppl (Stockh). 143:49–57. 1989.PubMed/NCBI
|
|
100
|
Litwin MS, Krementz ET, Mansell PW and Reed RJ: Topical chemotherapy of lentigo maligna with 5-fluorouracil. Cancer. 35:721–733. 1975.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Ryan RF, Krementz ET and Litwin MS: A role for topical 5-fluorouracil therapy in melanoma. J Surg Oncol. 38:250–256. 1988.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Calista D: Treatment of lentigo maligna with topical 1% cidofovir. Br J Dermatol. 157:421–423. 2007.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Montaudié H, Le Duff F, Butori C, Hofman V, Fontas E, Roger-Cruzel C, Bahadoran P, Perrot JL, Desmedt E, Legoupil D, et al: Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit. J Am Acad Dermatol. 82:731–733. 2020.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Gadaldi K, Feldmayer L, Yawalkar N and Hunger RE: Ingenol mebutate for lentigo maligna: A case report. Dermatology. 232 (Suppl 1):S24–S28. 2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Tio D, Prinsen CAC, Dréno B, Hoekzema R, Augustin M and van Montfrans C: Variation in the diagnosis and clinical management of lentigo maligna across Europe: A survey study among European association of dermatologists and venereologists members. J Eur Acad Dermatol Venereol. 32:1476–1484. 2018.PubMed/NCBI View Article : Google Scholar
|
